Candidemia incidence and associated 30-day mortality have risen in the United States since 2015, according to a study published yesterday in Clinical Infectious Diseases.
For the study, a team led by researchers with Houston Methodist Hospital examined data from a nationwide database of electronic health records to analyze trends in candidemia incidence from 2015 through 2014.
Candidemia is a severe and life-threatening bloodstream infection caused by species of Candida yeast. Most often found in medically vulnerable and chronically ill patients, Candida species cause an estimated 23,000 bloodstream infections every year in the United States, with mortality rates ranging from 25% to 40%.
The study authors note that the incidence of candidemia and candidemia-related mortality increased during the COVID-19 pandemic, when severely ill, intubated patients spent more time in hospitals. They wanted to see whether those trends have persisted and to assess changes in causative species.
A total of 29,454 candidemia cases were identified among 27,926 patients (mean age, 58.9 years; 55.6% male) across 141 healthcare systems. The overall incidence was 50.5 cases per 100,000 hospital admissions, rising from 42.3 in 2015 to 51.2 in 2024.
Overall 30-day mortality was 31.5%, increasing from 24.7% to 37.6% in 2021, then declining to 31.8%. The most common species was Candida albicans, accounting for 40% of candidemia cases over the study period. The proportion of infections caused by Candida auris, a multidrug-resistant yeast first identified in a US patient in 2016, rose to 4.7% by 2024.
An analysis of C auris patients found they were more likely to be Black, have renal failure, and have a higher Social Vulnerability Index than patients with candidemia caused by other species.
More ICU-acquired cases
The authors say the increase in candidemia-related mortality occurred in parallel with a shift toward intensive care unit (ICU)-acquired cases and a trend toward older patients that began during COVID and has persisted, “despite advances in prevention, diagnostics, and therapy.”
“Overall, these data suggest that candidemia is increasingly affecting medically vulnerable patients at high risk of mortality, such as the critically ill and elderly, and that important healthcare disparities exist with respect to C. auris,” they concluded.